Patient description: A 65-year-old male with a history of tuberculosis has started to complain of productive cough with tinges of blood. Chest X-ray reveals a round opaque mass within a cavity in his left upper lobe. The spherical mass moved in the cavity during supine and prone CT imaging. Culture of the sputum revealed an organism with septated, low-angle branching hyphae that had straight, parallel walls.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Psoriasis Subjects are non-immunocompromised males or females 18 years of age or older Subjects have moderate-to-severe (≥10% total body surface area) plaque psoriasis Subject diagnosed at least 6 months prior to entering the study Negative urine pregnancy test within 7 days before the first dose of ustekinumab in all women (except those surgically sterile or at least 5 years postmenopausal) Sexually active subjects of childbearing potential must agree to use medically acceptable form of contraception during screening and throughout the study Are considered eligible according to the following tuberculosis (TB) screening Have no history of latent or active TB prior to screening. An exception is made for subjects currently receiving treatment for latent TB with no evidence of active TB, or who have a history of latent TB and documentation of having completed appropriate treatment for latent TB within 3 years prior to the first administration of study agent. It is the responsibility of the investigator to verify the adequacy of previous antituberculous treatment and provide appropriate documentation Have no signs or symptoms suggestive of active TB upon medical history and/or physical examination Have had no recent close contact with a person with active TB or, if there has been such contact, will be referred to a physician specializing in TB to undergo additional evaluation and, if warranted, receive appropriate treatment for latent TB prior to or simultaneously with the first administration of study agent Within 1 month prior to the first administration of study agent, have a negative QuantiFERON-TB Gold test result, or have a newly identified positive QuantiFERON-TB Gold test result in which active TB has been ruled out and for which appropriate treatment for latent TB has been initiated either prior to or simultaneously with the first administration of study agent. The QuantiFERON-TB Gold test are not required at screening for subjects with a history of latent TB and ongoing treatment for latent TB or documentation of having completed adequate treatment as described above; Subjects with documentation of having completed adequate treatment as described above are not required to initiate additional treatment for latent TB  Subject is younger than 18 years of age Subject has less than 10% body surface involvement of his/her psoriasis Subjects with erythrodermic, pustular, or guttate psoriasis History of known or suspected intolerance to any of the ingredients of the investigational study product Evidence of skin conditions other than psoriasis that would interfere with study-related evaluations of psoriasis Evidence of active infections such as fevers, chills, sweats, or history of untreated Lyme disease and active severe infections within 4 weeks before screening visit, or between the screening and Week 0 visits Subject has a history of listeriosis, untreated TB, persistent or active infections requiring hospitalization or treatment with IV antibiotics, IV antiretrovirals, or IV antifungals within 30 days of baseline, or oral antibiotics, antivirals, or antifungals for purpose of treating infection, within 14 days of baseline Have a history of latent or active granulomatous infection, including histoplasmosis or coccidioidomycosis, prior to screening Refer to for information regarding with a history of latent TB Have had a Bacille Calmette-Guerin (BCG) vaccination within 12 months of screening